NEW YORK, June 17, 2021 /PRNewswire/ -- MindMed (NASDAQ:
MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech
company developing psychedelic-inspired therapies, has announced
the addition of Dr. Peter Bergethon,
a world-leading expert in neurology, digital medicine, and central
nervous system (CNS) drug development to the Company's Scientific
Advisory Board.
Dr. Bergethon is the Vice President and Head of Digital and
Quantitative Medicine at Biogen Inc., where he leads the effort to
transform clinical trials and humanize drug discovery by
encouraging the transition of clinical trial measures from a
qualitative to a quantitative discipline. The Quantitative Medicine
transformation has advanced Biogen's leadership in neuroscience
therapeutics and personalized medicine. Dr. Bergethon came to
Biogen in 2017 from Pfizer Worldwide Research and Development where
he was Vice President and Head of the Pfizer Innovation Research
Lab within the Early Clinical Development group.
Before joining the biopharmaceutical industry in 2012, Dr.
Bergethon spent 30 years in academic medicine as a Professor at
Boston University and Tufts University in the Departments of
Biochemistry, Neurology, Neurobiology & Anatomy, and Biomedical
Engineering. Dr. Bergethon graduated from Williams College with honors in biology for
research in neurocybernetics and then earned an M.D. from Jefferson
Medical College. He is board-certified in internal medicine and
neurology following dual residencies at Boston City Hospital. Dr.
Bergethon received his formal science training through the National
Institutes of Health's Physician-Scientist training in
biophysical chemistry at Boston University
School of Medicine. He then completed a fellowship training
in EEG and neurophysiology at Lahey Clinic-Hitchcock Medical Center
in Burlington, MA. In 1995, Dr.
Bergethon received the American Academy of Neurology's Founders'
Award. Dr. Bergethon has written and contributed to over 130
research papers and books and is the single author of "The Physical
Basis of Biochemistry: The Foundations of Molecular Biophysics",
2nd Ed.
MindMed CEO Robert Barrow said,
"We are thrilled to welcome Dr. Bergethon to our Scientific
Advisory Board. As we seek to revolutionize mental health and
addiction care, we continue to explore ways of leveraging
innovative digital medicine approaches to facilitate broad
accessibility and major public health impacts. Dr. Bergethon's
extensive experience in this field will be invaluable in
progressing all of our research and development efforts."
Dr. Bergethon stated, "My research and interests have always
centered around a core question: 'What are the physical and
systemic bases for creativity and intelligent behavior, and how
could such behavior be practically constructed or reconstructed?'
This core query continues to form the basis for the approach that
digital medicine takes toward transforming neuroscience
therapeutics. The ultimate thrust of my interest is the design,
construction, and operation of 'intelligent machines' inspired by
biological understanding. By any measure, I have lived a charmed
scientific existence."
MindMed's Scientific Advisory Board is composed of a diverse
group of members with expertise in psychiatry, neuroscience, and
clinical development. The Scientific Advisory Board leverages
decades of deep knowledge in biotech and psychiatry to guide
MindMed's development programs. Members represent institutions such
as Johns Hopkins, New York University Langone Health, Duke University, National Institutes of Health
(NIH), Stanford University, and
Albany Medical College.
Scientific Advisory Board Chair, Dr. Robert Malenka added, "We are very excited to
welcome Dr. Bergethon to the Scientific Advisory Board. He brings a
wealth of experience and innovative thinking to MindMed's digital
medicine efforts and will be invaluable in helping MindMed be the
world leader in developing effective new treatments based on the
most rigorous science."
About MindMed
MindMed is a clinical-stage biotech
company that discovers, develops and deploys psychedelic inspired
medicines and therapies to address addiction and mental health. The
Company is assembling a compelling drug development pipeline of
innovative treatments based on psychedelic substances including
psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The
MindMed executive team brings extensive biopharmaceutical
experience to MindMed's approach of developing the next generation
of psychedelic inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO exchange under the symbol MMED. MindMed is also traded
in Germany under the symbol MMQ.
For more information: www.mindmed.co
MindMed Forward-Looking Statements
Certain statements
in this news release related to the Company constitute
"forward-looking information" within the meaning of applicable
securities laws and are prospective in nature. Forward-looking
information is not based on historical facts, but rather on current
expectations and projections about future events and are therefore
subject to risks and uncertainties which could cause actual results
to differ materially from the future results expressed or implied
by the forward-looking statements. These statements generally can
be identified by the use of forward-looking words such as "will",
"may", "should", "could", "intend", "estimate", "plan",
"anticipate", "expect", "believe", "potential" or "continue", or
the negative thereof or similar variations. Forward-looking
information in this news release include statements regarding the
expertise of the Scientific Advisory Board and ability to leverage
the knowledge of the Scientific Advisory Board, the ability to
develop and the potential success of using technology to improve
health outcomes, the pursuit of strategic initiatives, and the
Company's intended future business plans and operations, including
the development of psychedelic inspired medicines and experiential
therapies. Although the Company believes that the expectations
reflected in such forward-looking information are reasonable, such
information involves risks and uncertainties, and undue reliance
should not be placed on such information, as unknown or
unpredictable factors could have material adverse effects on future
results, performance or achievements of the Company. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including
history of negative cash flows; limited operating history;
incurrence of future losses; availability of additional capital;
lack of product revenue; compliance with laws and regulations;
difficulty associated with research and development; risks
associated with clinical trials or studies; heightened regulatory
scrutiny; early stage product development; clinical trial risks;
regulatory approval processes; novelty of the psychedelic inspired
medicines industry; as well as those risk factors discussed or
referred to herein and the risks described under the headings "Risk
Factors" in the Company's filings with the securities regulatory
authorities in all of the provinces and territories of Canada and available under the Company's
profile on SEDAR at www.sedar.com and with the U.S. Securities and
Exchange Commission on EDGAR at www.sec.gov. Should one or more of
these risks or uncertainties materialize, or should assumptions
underlying the forward-looking information prove incorrect, actual
results and future events could differ materially from those
anticipated in such information. Although the Company has attempted
to identify important risks, uncertainties and factors that could
cause actual results to differ materially, there may be others that
cause results not to be as anticipated, estimated or intended.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend and does not assume any obligation to update this
forward-looking information.
Media Contact: mindmed@150bond.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mindmed-appoints-pharmaceutical-veteran-peter-bergethon-md-to-scientific-advisory-board-301314501.html
SOURCE Mind Medicine (MindMed) Inc.